LDS/Medical Tests/Non-Invasive Prenatal Testing (NIPT) for Fetal Aneuploidy

Non-Invasive Prenatal Testing (NIPT) for Fetal Aneuploidy

Non-Invasive Prenatal Testing (NIPT) is a genetic based testing used for prenatal screening for aneuploidy such as Down syndrome (trisomy 21), Patau syndrome (trisomy 13), and Edward syndrome (trisomy 18). In addition, some of new advanced NIPT technologies can detect other chromosomal abnormalities such as monosomy X or Turner Syndrome and microdeletion syndromes (Cri-du-chat syndrome, 1p36 deletion syndrome, DiGeorge syndrome).

The purpose of NIPT is to screen pregnancies for fetal aneuploidy when the fetus is at increased risk for chromosomal disorders (i.e. advanced maternal age, positive first trimester screen, previous history of aneuploidies, abnormality found on ultrasound) using non-invasive methods. NIPT has high detection rates, low numbers of false-positive results and avoid the potential for fetal harm from invasive sampling such as CVS or amniocentiesis. When abnormalities are detected the mother should be referred for diagnostic testing such as cytogenetic analysis (karyotyping), fluorescence in situ hybridization, quantitative fluorescence PCR (QF-PCR) which will require the collection of fetal cells through invasive procedures such as amniocentesis or chorionic villus sampling (CVS).

NIPT technology uses cell free fetal DNA in the serum or plasma of the pregnant women to detect fetal aneuploidy and offers higher sensitivity and specificity than the current standard screening tests. NIPT has been recommended by number of professional societies such as the American College of Obstetricians and Gynecologists (ACOG) to be used as a primary screening test in women at increased risk of aneuploidy, or as a follow-up test for women with a positive first-trimester or second-trimester maternal serum screening result. The test can be done any time between 10-22 weeks.

  • Prenatal screening for aneuploidy (Down syndrome, Patau syndrome, Edward syndrome)
  • Prenatal screening for other chromosomal abnormalities such as sex chromosome aneuploidies and microdeletion syndromes
Positive screen for trisomy (21, 18 or 13). Increased amounts of material from chromosome 13, 18 or 21 is usually reported as consistent with a trisomy of the identified chromosome.

Negative screen for aneuploidy Normal representation of material from chromosomes 13, 18, or 21.

Whole Genome Sequencing of serum or Plasma Cell-Free DNA, Next Generation Sequencing, Targeted sequencing with SNPs. Simply, circulating cell-free DNA is purified from the maternal serum or plasma and converted into a genomic DNA library for sequencing. Reads are aligned to the human genome, and a Z-score is generated for chromosomes 13, 18, and 21. In some methodologies, each sample is also evaluated for the presence or absence of Y chromosome material.

Whole blood with preservation of Cell-Free Circulating DNA. Blood should be collected in Streck tubes.

Stability

  • Ambient: 3-5 days
  • Refrigerated: 5-7 days
  • Frozen: Unacceptable
Amniocentesis or Chorionic villus sampling (CVS) to obtain fetal material for karyotyping, fluorescence in situ hybridization, or quantitative fluorescence PCR (QF-PCR) as confirmatory tests if screening is positive.
5-12 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login